39
Volume 3, Issue 1, May, 2023
For important information on contraindications, warnings, precautions, adverse reactions, interactions,
dosing, and conditions of clinical use, consult the Product Monographs at: www.takeda.com/en-ca/
cuvitrupm, www.takeda.com/en-ca/gammagard-liquidpm, www.takeda.com/en-ca/takhzyropm
The Product Monographs are also available by calling 1-800-268-2772.
CUVITRU® is a registered trademark of Baxalta Inc.
GAMMAGARD LIQUID® is a registered trademark of Baxalta Inc.
TAKHZYRO® is a registered trademark of Dyax Corp.
Takeda Canada Inc.
www.takeda.com/en-ca
TAKEDA
TM
and the TAKEDA Logo® are trademarks of Takeda
Pharmaceutical Company Limited, used under license.
© 2022 Takeda Pharmaceutical Company Limited.
All rights reserved.
PRMCDA/CA/CIN/0001
Takeda is committed to supporting
patients with immunodeficiency disorders
and hereditary angioedema
[
I
m
m
u
n
o
g
l
o
b
u
l
i
n
I
n
t
r
a
v
e
n
o
u
s
(
H
u
m
a
n
)
1
0
%
]
Pr
Gammagard Liquid® is an Immune Globulin Intravenous
(Human), [IVIG] 10% indicated for:
• Primary immunodeficiency
Replacement therapy in primary immunodeficiency
syndromes (PID) such as: congenital agammaglobulinaemia
and hypogammaglobulinaemia, common variable
immunodeficiency, severe combined immunodeficiency, and
Wiskott Aldrich syndrome.
• Secondary Immunodeficiency
Replacement therapy in secondary immunodeficiency
syndromes (SID) such as: B-cell chronic lymphocytic
leukemia, pediatric HIV infection, and allogeneic bone
marrow transplantation.
• Idiopathic thrombocytopenic purpura (ITP)
• Multifocal Motor Neuropathy (MMN)
Maintenance therapy to improve muscle strength and
disability in adult patients with MMN.
GAMMAGARD LIQUID should be administered under
the supervision of a qualified health professional who is
experienced in the use of immunoglobulins and in the
management of PID, SID and ITP. Appropriate management
of therapy and complications is only possible when adequate
diagnostic and treatment facilities are readily available.
Pr
CUVITRU® is an Immunoglobulin Subcutaneous (Human) (IGSC),
20% Liquid indicated as replacement therapy for primary humoral
immunodeficiency (PI) and secondary humoral immunodeficiency
(SI) in adult and pediatric patients two years of age and older.
Pr
TAKHZYRO® (lanadelumab injection) is indicated for routine
prevention of attacks of hereditary angioedema (HAE) in
adolescents and adults. TAKHZYRO is not intended for acute
treatment of HAE attacks.
